Correlation of C-reactive protein with survival and radiographic response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer.
ABSTRACT This study was conducted to assess the prognostic role of regular measurements of C-reactive protein (CRP) in patients with advanced-stage non-small cell lung cancer (NSCLC) during platinum-based first-line therapy.
A total of 210 patients were retrospectively analyzed regarding CRP values, infections, histological type, stage, performance status, gender, age, body mass index and survival. Additionally, in 88 of these patients, changes of CRP values were correlated with response to chemotherapy by radiographic imaging.
Elevation of CRP prior to the first cycle was an adverse prognostic factor for overall survival. Comparing CRP values before and after 2 cycles correlated with response and identified patient groups with a remarkable difference of overall survival (18.8 vs. 7.5 months). Normalization of CRP was associated with a low risk for progression, whereas patients with an increase of CRP values of more than 25% showed a progressive disease in most cases. Besides performance status, no correlation of CRP with other clinical data was found.
Measurement of CRP before initiation and during a platinum-based chemotherapy can provide prognostic information for the individual patient with advanced NSCLC and is able to support or even replace assessment of response by radiographic imaging in defined situations.
- SourceAvailable from: PubMed Central[Show abstract] [Hide abstract]
ABSTRACT: Lung cancer is most common cause of cancer-related mortality worldwide. Non-small-cell lung carcinoma (NSCLC) is disease with very low 5-year relative survival rate. For patients with non-small cell lung cancer, roles of current treatments are to prolong survival time and to improve quality of life.Medical Archives 01/2014; 68(2):83-5.
- [Show abstract] [Hide abstract]
ABSTRACT: In non-small cell lung cancer patients (NSCLC), median survival from the time patients develop bone metastasis is classically described being inferior to 6 months. We investigated the subcategory of patients having an inaugural skeletal-related-event revealing NSCLC. The purpose of this study was to assess the impact of bone involvement on overall survival and to determine biological and tumoral prognosis factors on OS and PFS. An analysis of the subgroup of solitary bone metastasis patients was also performed.BMC Cancer 06/2014; 14(1):416. · 3.32 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: The basic uses of C-reactive protein (CRP) and procalcitonin (PCT) in clinical practice are in the diagnosis and follow-up of infectious disease. The fact that CRP already achieves high levels in cases with lung cancer, however, limits its diagnostic specificity. Procalcitonin may be an important marker in the differential diagnosis of lung cancer patients who have fever and high CRP levels. Our objective in this study was to determine the levels of CRP and PCT in patients with newly diagnosed non-infectious non-small cell lung cancer (NSCLC) and to relate these results to patient and disease characteristics. Serum CRP and PCT levels were measured in 79 histopathologically proven NSCLC patients and 20 healthy controls. Results were compared with demographic and clinical variables in patients with NSCLC. Serum CRP concentrations were significantly higher in NSCLC patients compared to the control group [38.30 (7.79-185) mg/dl vs. 7.79 (3.36-26.10) mg/dl; p < 0.001]. There was no significant difference between the two groups in PCT levels (p > 0.05). A mild, positive correlation was found between CRP level and tumor diameter. When comparing CRP levels in the lung cancer patients grouped according to age, sex, smoking status, clinical TNM staging and performance status (PS), the only significant difference found was that for PS score. High serum CRP levels in non-infectious NSCLC patients are mainly related to PS status and weakly to tumor size. Adding serum PCT measurement may contribute to exclusion of infections in patients with NSCLC.Contemporary Oncology / Wspólczesna Onkologia 01/2013; 17(1):68-72. · 0.22 Impact Factor